# BIOLOGIC AND THERAPEUTIC RESEARCH IN MULTIPLE MYELOMA

> **NIH NIH R01** · UNIVERSITY OF TX MD ANDERSON CAN CTR · 1987 · $207,021

## Abstract

A broad range of biologic and clinical studies of multiple myeloma
will be conducted to define the mechanisms of drug resistance.
Laboratory research will be integrated with a clinical program
using high dose melphalan and total body irradiation (supported by
bone marrow transplantation) as a consolidation therapy after
VAD-induced remission or as a salvage program for VAD failure.
The main clinical goal is to maximize tumor cytoreduction using 2
highly effective and non-cross resistant regimens, so that long
term disease control and perhaps cure of this B cell neoplasm can
be accomplished.  Laboratory studies will define the myeloma
tumor genotype and phenotypic features associated with drug
resistance and examine relapse in the context of clonal
evaluation.  In this endeavor, cytometric, cytogenetic and
molecular genetic studies will be employed to provide a
comprehensive evaluation of myeloma plasma cells during defined
stages of the clinical program at diagnosis, in remission and at
relapse.  The unique therapeutic approach will provide the great
opportunity to study fundamentally important areas of myeloma
and cancer biology in general, i.e. clonal evaluation, drug
resistance and potential obstacles to cure despite supralethal
cytotoxic therapy.

## Key facts

- **NIH application ID:** 3174916
- **Project number:** 2R01CA037161-04
- **Recipient organization:** UNIVERSITY OF TX MD ANDERSON CAN CTR
- **SAM.gov UEI:** S3GMKS8ELA16
- **Principal Investigator:** BART BARLOGIE
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $207,021
- **Award type:** 2
- **Project period:** 1984-09-01 → 1990-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3174916

## Citation

> US National Institutes of Health, RePORTER application 3174916, BIOLOGIC AND THERAPEUTIC RESEARCH IN MULTIPLE MYELOMA (2R01CA037161-04). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3174916. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*